From Nasdaq: 2024-04-26 18:15:13

Insulet (PODD) closed at $166.19, up 1.23% from the previous session, outpacing the S&P 500. In the past month, the stock fell by 4.22%, underperforming the Medical sector and S&P 500. Insulet’s upcoming earnings release on May 9, 2024 projects an EPS of $0.39, a 69.57% increase from the previous year.

Insulet’s full-year earnings estimate is $3.08 per share, with revenue expected to reach $1.96 billion, a 15.7% increase from the prior year. Analyst estimates have been adjusted, reflecting short-term business trends. The Zacks Rank system, based on these estimates, rates Insulet at #3 (Hold).

Insulet’s Forward P/E ratio stands at 53.38, higher than the industry average of 20.69. The PEG ratio of 2.96 indicates a premium valuation. With a Zacks Industry Rank of 140, the Medical – Products sector falls in the bottom 45%. Top industries outperform the bottom half 2 to 1, making Zacks.com a valuable tool for monitoring stock metrics.



Read more at Nasdaq: Insulet (PODD) Outperforms Broader Market: What You Need to Know